The main strength of our study is that it is the first one investigating serum o-α-synuclein and p-tau181 as discriminating biomarkers for PD and PSP, showing that these two biomarkers are not clinically useful when assessed in this body fluid. The gene discussed is SNCA; the disease is supranuclear palsy, progressive, 1.